Internet-based Positive Psychological Intervention for Hispanic/Latino Adult With Hypertension in a Primary Care Setting

The largest epidemiologic study of Hispanic/Latino participants thus far, i.e., the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) documented that 80% of men and 71% of women have at least one major cardiovascular disease (CVD) risk factor. The American Heart Association emphasizes that current CVD prevention efforts are sparse and ineffectual in minority populations and acknowledges the need for new and more effective disease prevention strategies. This proof-of-concept study and pilot randomized clinical trial seeks to implement and evaluate a novel internet-based 5-week Positive Psychology (PP) Intervention (compared to an attention control condition) in Hispanic/Latino adults with uncontrolled hypertension, i.e., elevated 24-hour ambulatory blood pressure, with primary interest in testing efficacy for clinically meaningful improvements in cardiovascular function.

Study Overview

Detailed Description

The study features piloting of a randomized trial to determine whether an internet-based positive psychology (PP) intervention is associated with greater improvements in blood pressure compared to an attention control condition. The pilot trial additionally evaluates the efficacy of the internet-based PP intervention with respect to psychological well-being, hypertension-related health behaviors, autonomic cardiac control, and high-sensitivity C-reactive protein. Serum blood assays will facilitate exploration of mechanistic indicators linking psychological well-being to cardiac functioning.

Study Type

Interventional

Enrollment (Anticipated)

70

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Illinois
      • Chicago, Illinois, United States, 60608
        • Recruiting
        • UI Health Pilsen Family Health Center Lower West
        • Contact:
          • Maura Stefko-Woznika, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Hispanics/Latinos recruited from UI Health Pilsen Family Health Center Lower West
  • Aged ≥18
  • Fluent in English or Spanish with ≥8th grade education
  • Elevated sitting blood pressure (≥140/90)
  • Ability to read and understand the informed consent
  • Ability to access internet from home or in public setting (note, tablet PCs will be made available to all enrolled participants at no charge), and
  • Self-reported comfort in with handling of a table computer and website navigation.

Exclusion Criteria:

  • Cognitive impairment denoting dementia (assessed using the Short Portable Status Questionnaire-See Appendix E)
  • Severely reduced life expectancy (e.g., self-reported diagnosis of metastatic cancer, congestive heart failure, or end-stage kidney disease)
  • Self-reported diagnosis of sickle cell disease
  • Skin damage or rash in the upper arm region where ambulatory blood pressure monitor is to be placed
  • Currently enrolled in psychotherapy, and
  • Self-reported history or current diagnosis of bipolar disorder, dissociative disorder, psychosis, or substance abuse; or have severe depression.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Internet-based Positive Psychological Intervention
The investigator's culturally-tailored internet-based Positive Psychology (PP) Intervention is a non-pharmacotherapy approach aimed at increasing positive emotional experiences by teaching individuals to engage in intentional activities known to increase psychological and emotional well-being through targeting of constructs such as optimism, gratitude, mindfulness/relaxation, and resilience.
The investigator's culturally-tailored internet-based Positive Psychology Intervention is a non-pharmacotherapy approach aimed at increasing positive emotional experiences by teaching individuals to engage in intentional activities known to increase psychological and emotional well- being, e.g., mindfulness/meditation. The current 5-week Internet-based intervention will be delivered via a secure website which participants will access at home (or in a public setting with Wi-Fi) using an assigned username and password. The on-line program includes didactic material and "home practice" with participants logging into the website 3-4 times per week for 15 to 20 minute sessions. In addition to weekly on-line instruction, participants are assigned homework as a means of incorporating skills learned into their day-to-day activities.
Other Names:
  • Positive Affect Intervention
No Intervention: Attention Control Group
Participants will complete computerized surveys to document the frequency of positive and negative emotions experienced in daily life. The attention control group will be given the option to access our positive psychological intervention and associated content via the web at the conclusion of the 12-week data collection phase.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from Baseline Ambulatory Blood Pressure at 5- and 12-weeks
Time Frame: Baseline, 5-, and 12-weeks
The ambulatory blood pressure monitor (the Spacelabs Healthcare 90217A ABPM) will capture 24-hour daytime and nighttime systolic and diastolic blood pressure reading in the natural environment and will capture heart rate variability. The ambulatory blood pressure monitor will record the subject's systolic and diastolic blood pressure periodically every 30 minutes to one hour and the data will be stored in the internal memory until uploaded to a companion application for visualization and analysis. In addition to ambulatory blood pressure the wearable device will record pulse waves on a beat to beat basis from which heart rate variability will be calculated and analyzed.
Baseline, 5-, and 12-weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Center for Epidemiological Studies Depression Scale: Change from Baseline Depressive Symptoms at 5- and 12-weeks
Time Frame: Baseline, 5-, and 12-weeks
Center for Epidemiological Studies Depression-Scale. The total score is computed. Scores range from 0-60, with higher scores indicating greater symptoms of depression.
Baseline, 5-, and 12-weeks
Life Orientation Test-Revised: Change from Baseline Dispositional Optimism at 5- and 12-weeks
Time Frame: Baseline, 5-, and 12-weeks
Life Orientation Test-Revised. Two sub-scale scores are computed for affirming optimism and disaffirming pessimism. Scores range from 0-12 on each sub-scale and summed, with higher scores indicating greater optimism.
Baseline, 5-, and 12-weeks
General Well-being Schedule: Change in Baseline Emotional Vitality at 5- and 12-weeks
Time Frame: Baseline, 5-, and 12-weeks
General Well-being Schedule
Baseline, 5-, and 12-weeks
Life Engagement Test: Change in Baseline Life engagement and Meaning at 5- and 12-weeks
Time Frame: Baseline, 5-, and 12-weeks
Life Engagement Test
Baseline, 5-, and 12-weeks
Perceived Stress Scale: Change from Baseline Perceived Stress at 5- and 12-weeks
Time Frame: Baseline, 5-, and 12-weeks
Perceived Stress Scale. The total score is computed. Scores range from 0 to 16, with higher scores indicating greater perceived stress.
Baseline, 5-, and 12-weeks
Modified Differential Emotions Scale: Change from Baseline Positive and Negative Affect at 5- and 12-weeks
Time Frame: Baseline, 5-, and 12-weeks
Modified Differential Emotions Scale. Two sub-scale scores are computed for positive emotions and negative emotions. The sub-scales are averaged, with higher scores indicating higher positive or negative emotions.
Baseline, 5-, and 12-weeks
Positive Skills: Change in Baseline Positive Skills at 5- and 12-weeks
Time Frame: Baseline, 5-, and 12-weeks
Positive Skills
Baseline, 5-, and 12-weeks
Medical Outcomes Study Social Support Survey: Change in Baseline Perceived Social Support at 5- and 12-weeks
Time Frame: Baseline, 5-, and 12-weeks
Medical Outcomes Study Social Support Survey. Four sub-scale scores are computed for 1) emotional/informational support 2) Tangible support 3) Affectionate Support and 4)Positive Social Interaction. An additional item asks the participant to quantify the number of persons of support. Sub-scale scores range from 1-5, and they are summed for a total score for perceived social support ranging from 0-25, with higher scores indicating greater perceived support.
Baseline, 5-, and 12-weeks
Medication Adherence: Change in Baseline Medication Adherence at 5- and 12-weeks
Time Frame: Baseline, 5-, and 12-weeks
Medication Adherence
Baseline, 5-, and 12-weeks
12-Item Short Form Survey: Change in Self-Reported Mental and Physical Health at 5- and 12-weeks
Time Frame: Baseline, 5-, and 12-weeks
12-Item Short Form Survey. The total score is computed. Scores range from 0-100, with higher scores indicating greater perceived physical and mental health.
Baseline, 5-, and 12-weeks

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Physical Activity: Change in Hypertension-related Health Behavior(s)
Time Frame: Baseline, 5-, and 12-weeks
Self-Reported Physical Activity
Baseline, 5-, and 12-weeks
Diet: Change in Hypertension-related Health Behavior(s)
Time Frame: Baseline, 5-, and 12-weeks
Sodium Intake Diet using Scored Sodium Questionnaire. The total score is computed. Scores range from 0-215, with higher scores indicating greater sodium intake.
Baseline, 5-, and 12-weeks
Change in Heart Rate Variability
Time Frame: Baseline, 5-, and 12-weeks
Beat-to-beat interval
Baseline, 5-, and 12-weeks
Change in High-sensitivity C-Reactive Protein
Time Frame: Baseline, 5-, and 12-weeks
mg/L
Baseline, 5-, and 12-weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Rosalba Hernandez, PhD, University of Illinois at Urbana-Champaign

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 12, 2019

Primary Completion (Anticipated)

January 1, 2021

Study Completion (Anticipated)

June 1, 2021

Study Registration Dates

First Submitted

March 25, 2019

First Submitted That Met QC Criteria

March 25, 2019

First Posted (Actual)

March 27, 2019

Study Record Updates

Last Update Posted (Actual)

July 5, 2019

Last Update Submitted That Met QC Criteria

July 2, 2019

Last Verified

July 1, 2019

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 08776

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Yes

IPD Plan Description

The investigator will make the data available to users only under a data-sharing agreement that provides for: (1) a commitment to use data only for research purposes and not to identify any individual participant; (2) a commitment to secure the data using appropriate technology; and (3) a commitment to destroy or return data after analyses are completed. If additional outputs result from this research that would be appropriate to share with a wider audience, the investigator will work with the Research Data Service at the University Library to determine appropriate venues for archiving and sharing.

IPD Sharing Time Frame

Data may be available by 2022 for a 5-year period.

IPD Sharing Access Criteria

The investigator will make the data available to users only under a data-sharing agreement that provides for: (1) a commitment to use data only for research purposes and not to identify any individual participant; (2) a commitment to secure the data using appropriate technology; and (3) a commitment to destroy or return data after analyses are completed. If additional outputs result from this research that would be appropriate to share with a wider audience, the investigator will work with the Research Data Service at the University Library to determine appropriate venues for archiving and sharing.

IPD Sharing Supporting Information Type

  • Study Protocol
  • Informed Consent Form (ICF)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe